ST. LOUIS, Aug. 29 - CMS, Inc., an Elekta Company and
worldwide leader in radiation treatment planning and workflow management
solutions, today announced that three sites have delivered clinical
treatments utilizing Monaco(TM), its next-generation Intensity Modulated
Radiotherapy (IMRT) treatment planning system. Allegheny General Hospital
in Pittsburgh, Pennsylvania, Erasmus Medical Center in Rotterdam,
Netherlands, and Froedtert Memorial Lutheran Hospital in Milwaukee,
Wisconsin, have all begun producing treatment plans with the application.
Featuring biological modeling, constrained optimization, and Monte
Carlo dose calculation algorithms, Monaco represents a fundamentally new
approach to IMRT planning, including a unique and sophisticated set of
tools to make the radiotherapy planning process easier, more
straightforward and clinically reliable.
“The biologically-based Monaco IMRT treatment planning system produces
clinically relevant plans, which are dosimetrically superior to plans from
dose-based IMRT treatment planning systems, feature shorter plan delivery
times, and can be easily verified with normal QA procedures,” says Moyed
Miften, Ph.D., DABR, and Allegheny General Hospital’s Chief of Medical
Physics. “The multi-criteria optimization and the sensitivity analysis
tools in the Monaco system also help reduce the time needed to optimize
IMRT plans.”
While IMRT delivers significant improvements for radiation treatment,
the technology presents challenges, including managing the time and
resource intensive processes associated with planning. With Monaco, CMS
offers new approaches that improve IMRT planning in the following ways:
— Sensitivity Analysis tool that minimizes trial-and-error by guiding
the decision making process
— Smart Sequencing(TM), a constrained aperture optimization that
produces efficient step-and-shoot segments
— Biological models, voxel definition controls, and multi-criterial
goals that provide more intuitive and direct control over the optimization
process
Monaco was developed with the University of Tubingen in Germany. Markus
Alber, Ph.D., and colleagues developed the Hyperion project, which is the
engine behind the new Monaco system. CMS commercialized these innovative
concepts and approaches from the Hyperion project to create the foundation
for Monaco. The result is an advanced, clinically sophisticated IMRT
planning system backed by the core research and capabilities of one of the
world’s leading research institutions.
About CMS
CMS, Inc., an Elekta Company, is a worldwide market leader in radiation
treatment planning and workflow management, combining innovative software
applications and advanced technology tools to deliver comprehensive
treatment planning and workflow management solutions that integrate
seamlessly in any clinical environment. With a commitment to product
excellence and a reputation for world-class service and support, CMS makes
all members of the treatment team more effective in providing patient care.
CMS is part of the Elekta Group, providing oncologists, radiation
therapists, neurosurgeons and many other medical specialists with state of
the art tools to fight cancer and brain disorders.
With more than 2,500 employees globally, Elekta’s corporate
headquarters are located in Stockholm, Sweden and the company is listed on
the Nordic Exchange under the ticker EKTAb. More information can be found
at http://www.cmsrtp.com and http://www.elekta.com
SOURCE CMS, Inc.